SOT109 is the first of SOTIO’s two next-generation ADC programs entering the clinic in 2026, reflecting the company’s broader strategy to build a differentiated solid tumor ADC franchise.
SOT109 is the first of SOTIO’s two next-generation ADC programs entering the clinic in 2026, reflecting the company’s broader strategy to build a differentiated solid tumor ADC franchise.